Compare IROQ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IROQ | PRLD |
|---|---|---|
| Founded | 1883 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.4M | 69.1M |
| IPO Year | 2011 | 2020 |
| Metric | IROQ | PRLD |
|---|---|---|
| Price | $26.25 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.0K | ★ 445.3K |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 157.16 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $27,979,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.42 | ★ N/A |
| Revenue Growth | 24.68 | ★ 250.00 |
| 52 Week Low | $22.04 | $0.61 |
| 52 Week High | $26.50 | $4.22 |
| Indicator | IROQ | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 52.65 |
| Support Level | $26.05 | $1.30 |
| Resistance Level | $26.46 | $1.56 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 72.22 | 83.92 |
IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.